Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Christine Edry Seidman, M.D.

Co-Author

This page shows the publications co-authored by Christine Seidman and Neal Lakdawala.
Connection Strength

1.857
  1. Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2021 02; 14(1):e003062.
    View in: PubMed
    Score: 0.235
  2. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2020 01 01; 5(1):83-91.
    View in: PubMed
    Score: 0.220
  3. The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. Mol Genet Genomic Med. 2019 11; 7(11):e940.
    View in: PubMed
    Score: 0.215
  4. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb; 3(2):180-8.
    View in: PubMed
    Score: 0.154
  5. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012 Oct 01; 5(5):503-10.
    View in: PubMed
    Score: 0.133
  6. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 Feb 16; 366(7):619-28.
    View in: PubMed
    Score: 0.128
  7. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012 Apr; 18(4):296-303.
    View in: PubMed
    Score: 0.128
  8. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010 Aug 05; 363(6):552-63.
    View in: PubMed
    Score: 0.115
  9. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):320-9.
    View in: PubMed
    Score: 0.111
  10. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 Oct; 27(10):1818-1824.
    View in: PubMed
    Score: 0.062
  11. Contribution of Noncanonical Splice Variants to TTN Truncating Variant Cardiomyopathy. Circ Genom Precis Med. 2021 Oct; 14(5):e003389.
    View in: PubMed
    Score: 0.062
  12. Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
    View in: PubMed
    Score: 0.060
  13. Expanding the clinical and genetic spectrum of ALPK3 variants: Phenotypes identified in pediatric cardiomyopathy patients and adults with heterozygous variants. Am Heart J. 2020 07; 225:108-119.
    View in: PubMed
    Score: 0.056
  14. Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 03 19; 139(12):1559-1560.
    View in: PubMed
    Score: 0.052
  15. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 10 02; 138(14):1387-1398.
    View in: PubMed
    Score: 0.050
  16. A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017 Oct; 10(5).
    View in: PubMed
    Score: 0.047
  17. A novel custom resequencing array for dilated cardiomyopathy. Genet Med. 2010 May; 12(5):268-78.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.